Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
Phase 2
Completed
- Conditions
- Anxiety Disorders
- Registration Number
- NCT00108836
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Current doctor's diagnosis of generalized anxiety disorder
- In need of psychiatric treatment
- Willingness to complete all aspects of the study
Exclusion Criteria
- Current doctor's diagnosis of major depression
- History of schizophrenia or schizoaffective disorders
- Drug dependence within 2 months prior to study start
For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:
www.novartisclinicaltrials.com
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mean reduction in anxiety from baseline to week 6
- Secondary Outcome Measures
Name Time Method The difference on day 4 in effect between placebo and the individual doses of XBD173 on reduction in anxiety and depression Pharmacokinetic assessments at baseline Pharmacogenetic assessments at baseline Pharmacogenomic and proteomic assessments at baseline Metabonomic assessments at visits 4, 7 and 10
Trial Locations
- Locations (1)
Investigational Site
🇨🇦Sherbrooke, Quebec, Canada